<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article87</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/LoDoCo2" style="display:block; margin-bottom:10px;">LoDoCo2 Original</a></li>
<h2><strong>LoDoCo2</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Colchicine in Patients with Chronic Coronary Disease".The New England Journal of Medicine. 2020.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does colchicine reduce the risk of cardiovascular events in patients with chronic coronary disease?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Colchicine at a dose of 0.5 mg once daily reduced the risk of cardiovascular events in patients with chronic coronary disease when compared to placebo.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines do not include recommendations on the use of colchicine for chronic coronary disease (as of the knowledge cutoff date).<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, controlled, double-blind, event-driven trial.<br/>
- N=5,552.<br/>
- Colchicine 0.5mg once daily (n=2,762).<br/>
- Placebo (n=2,760).<br/>
- Enrollment: 2014-2018 <br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Adults aged 35-82 years with evidence of chronic coronary disease.<br/>
- Exclusion criteria included moderate-to-severe renal impairment, severe heart failure, severe valvular heart disease, or known adverse effects from colchicine.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Colchicine 0.5 mg once daily or matching placebo after a 1-month open-label run-in period.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary: A composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization.<br/>
- Secondary: A composite of cardiovascular death, spontaneous myocardial infarction, or ischemic stroke.<br/>
- Other outcomes: Spontaneous myocardial infarction or ischemia-driven coronary revascularization and others.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The trial population included a lower percentage of women than expected based on the prevalence of chronic coronary disease in the general population. <br/>
- Blood pressure and lipid levels were not collected at baseline or during the trial; therefore, outcomes according to risk-factor control could not be reported. <br/>
- There was no routine measurement of C-reactive protein or other inflammatory markers.<br/>
- The difference in noncardiovascular death rates between groups was not statistically significant but could be a potential concern.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- The National Health Medical Research Council of Australia and several other agencies and organizations.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Colchicine Cardiovascular Outcomes Trial (COLCOT) <br/>
- Original Low-Dose Colchicine (LoDoCo) trial<br/>
- "Colchicine in Patients with Acute Coronary Syndrome", New England Journal of Medicine.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
